Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Tax Provisions (2016 - 2024)

Vistagen Therapeutics' Tax Provisions history spans 12 years, with the latest figure at $7000.0 for Q3 2024.

  • For Q3 2024, Tax Provisions changed N/A year-over-year to $7000.0; the TTM value through Jun 2025 reached $7000.0, up 55.56%, while the annual FY2025 figure was $7000.0, 75.0% up from the prior year.
  • Tax Provisions for Q3 2024 was $7000.0 at Vistagen Therapeutics, up from $1500.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $7000.0 in Q3 2024 and bottomed at $1000.0 in Q1 2020.
  • The 4-year median for Tax Provisions is $3000.0 (2020), against an average of $3150.0.
  • The largest annual shift saw Tax Provisions surged 50.0% in 2020 before it rose 13.33% in 2021.
  • A 4-year view of Tax Provisions shows it stood at $3000.0 in 2020, then increased by 13.33% to $3400.0 in 2021, then fell by 11.76% to $3000.0 in 2023, then surged by 133.33% to $7000.0 in 2024.
  • Per Business Quant, the three most recent readings for VTGN's Tax Provisions are $7000.0 (Q3 2024), $1500.0 (Q1 2024), and $3000.0 (Q2 2023).